Samsung BioLogics Co., Ltd. consigned development of candidate materials for Panoros anti-cancer drugs
Samsung BioLogics Co., Ltd. consigned development of candidate materials for Panoros anti-cancer drugs
  • 박정도
  • 승인 2020.09.17 14:20
  • 최종수정 2020.09.17 13:56
  • 댓글 0
이 기사를 공유합니다

 

[Infostock Daily=Reporter Park Jeong-Do] Samsung BioLogics announced on the 17th that it has signed a contract with Panoros Bioscience for the development of a contract for PB101, a candidate for anticancer drugs.

Samsung BioLogics plans to provide pre-CDO (pre-clinical) services such as process development, clinical sample production and support for submission of clinical trial plans (IND), and pre-clinical and clinical substance production from the development of cell lines of PB101.

PB101 is a target of all the genera of VEGF, an neovascularization factor that is overexpressed around cancer cells, and acts to inhibit the growth of cancer cells.

PB101 is a substance that requires a high level of research because of its complex protein structure. Samsung Bio Logics has established a customized strategy for PB101 development

Reporter Park Jeong-Do newface0301@naver.com


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.